Alexandra Elizabeth Shields1, Mehdi Najafzadeh2, Anna Boonin Schachter3. 1. Harvard/MGH Center on Genomics, Vulnerable Populations & Health Disparities, Mongan Institute for Health Policy, Massachusetts General Hospital, 50 Staniford Street, Suite 901 Boston, MA 02114, USA ; Department of Medicine, Harvard Medical School, 25 Shattuck St Boston, MA 02115, USA. 2. Division of Pharmacoepidemiology & Pharmacoeconomics, Department of Medicine, Brigham & Women's Hospital, 1620 Tremont Street, Suite 3030, Boston, MA 02120, USA. 3. Harvard/MGH Center on Genomics, Vulnerable Populations & Health Disparities, Mongan Institute for Health Policy, Massachusetts General Hospital, 50 Staniford Street, Suite 901 Boston, MA 02114, USA.
Abstract
AIM: To assess potential barriers to clinical integration of tailored smoking cessation treatment among African American and white smokers in the USA. METHODS: A total of 392 smokers (203 white and 189 African American) identified within a national random digit dial survey (response rate: 40.1%; 81.2% among households with whom we were able to make contact) of 1200 African Americans and 1200 white Americans. Respondents answered several closed-ended survey items addressing beliefs regarding what influences a smoker's ability to quit, past pharmacotherapy use, and their willingness to undergo genetic assessment in order to be matched to optimal treatment, among other items. RESULTS: In this first nationally representative survey of US smokers, 77% of respondents expressed willingness to undergo genetic testing in order to be matched to optimal pharmacotherapy, yet only 18% had ever used pharmacotherapy in a previous quit attempt. Smokers who rated 'medications and counseling' as very important in quitting were significantly more likely to endorse genetic testing (odds ratio [OR]: 8.94; 95% CI: 1.86-43.06), while those rating 'having God's help' as very important were significantly less likely to express willingness to undergo testing (OR: 0.11; 95% CI: 0.02-0.71). African American smokers were more likely than white smokers to express willingness to undergo genetic testing (OR: 3.80; 95% CI: 1.09-13.22), despite lower rates of previous pharmacotherapy use. CONCLUSION: While smokers reported high rates of willingness to undergo genetic testing to be matched to optimal treatment, these results suggest that smokers' willingness to use medications indicated by genetic test results may prove a significant barrier to realizing the promise of tailored smoking cessation treatment. The role of spirituality in smokers' willingness to use medication is an area for further study.
AIM: To assess potential barriers to clinical integration of tailored smoking cessation treatment among African American and white smokers in the USA. METHODS: A total of 392 smokers (203 white and 189 African American) identified within a national random digit dial survey (response rate: 40.1%; 81.2% among households with whom we were able to make contact) of 1200 African Americans and 1200 white Americans. Respondents answered several closed-ended survey items addressing beliefs regarding what influences a smoker's ability to quit, past pharmacotherapy use, and their willingness to undergo genetic assessment in order to be matched to optimal treatment, among other items. RESULTS: In this first nationally representative survey of US smokers, 77% of respondents expressed willingness to undergo genetic testing in order to be matched to optimal pharmacotherapy, yet only 18% had ever used pharmacotherapy in a previous quit attempt. Smokers who rated 'medications and counseling' as very important in quitting were significantly more likely to endorse genetic testing (odds ratio [OR]: 8.94; 95% CI: 1.86-43.06), while those rating 'having God's help' as very important were significantly less likely to express willingness to undergo testing (OR: 0.11; 95% CI: 0.02-0.71). African American smokers were more likely than white smokers to express willingness to undergo genetic testing (OR: 3.80; 95% CI: 1.09-13.22), despite lower rates of previous pharmacotherapy use. CONCLUSION: While smokers reported high rates of willingness to undergo genetic testing to be matched to optimal treatment, these results suggest that smokers' willingness to use medications indicated by genetic test results may prove a significant barrier to realizing the promise of tailored smoking cessation treatment. The role of spirituality in smokers' willingness to use medication is an area for further study.
Entities:
Keywords:
genetic testing; pharmacogenomic treatment for smoking; pharmacogenomics; pharmacotherapy; racial differences in pharmacotherapy use; smoking
Authors: Steven S Fu; Diana Burgess; Michelle van Ryn; Dorothy K Hatsukami; Jody Solomon; Anne M Joseph Journal: Prev Med Date: 2006-12-18 Impact factor: 4.018
Authors: F Patterson; R A Schnoll; E P Wileyto; A Pinto; L H Epstein; P G Shields; L W Hawk; R F Tyndale; N Benowitz; C Lerman Journal: Clin Pharmacol Ther Date: 2008-04-02 Impact factor: 6.875
Authors: Elyse R Park; Susan Kleimann; Emily J Youatt; Abigail Lockhart; Eric G Campbell; Douglas E Levy; Chanita Hughes Halbert; Erin Schmieder; Rasika Krishna; Alexandra E Shields Journal: Addict Behav Date: 2011-02-25 Impact factor: 3.913
Authors: Brian K Ahmedani; Edward L Peterson; Karen E Wells; Cynthia S Rand; L Keoki Williams Journal: Ann Allergy Asthma Immunol Date: 2012-12-07 Impact factor: 6.347
Authors: Louie E Ross; Ingrid J Hall; Temeika L Fairley; Yhenneko J Taylor; Daniel L Howard Journal: J Altern Complement Med Date: 2008-10 Impact factor: 2.579
Authors: Michael J Hall; Sharon L Manne; Ronald E Myers; Eileen M Keenan; Andrew M Balshem; David S Weinberg Journal: Genome Med Date: 2012-11-29 Impact factor: 11.117
Authors: Nicole Senft; Maureen Sanderson; Rebecca Selove; William J Blot; Stephen King; Karen Gilliam; Suman Kundu; Mark Steinwandel; Sarah J Sternlieb; Shaneda Warren Andersen; Debra L Friedman; Erin Connors; Mary Kay Fadden; Matthew Freiberg; Quinn S Wells; Juan Canedo; Rachel F Tyndale; Robert P Young; Raewyn J Hopkins; Hilary A Tindle Journal: Cancer Epidemiol Biomarkers Prev Date: 2019-06-03 Impact factor: 4.254
Authors: Chandrama Mukherjee; Kevin M Sweet; Jasmine A Luzum; Mahmoud Abdel-Rasoul; Michael F Christman; Joseph P Kitzmiller Journal: Per Med Date: 2017-09-01 Impact factor: 2.512